Global Nuclear Medicine Diagnostic (PET and SPECT) Market Estimated to Touch USD 19.48 Billion in 2021
The global nuclear medicine diagnostic (PET and SPECT) market accounted to USD 11.01 billion in 2016 and is estimated to touch USD 19.48 billion in 2021
July 13, 2017 /MarketersMedia/ —
The global nuclear medicine diagnostic (PET and SPECT) market accounted to USD 11.01 billion in 2016 and is estimated to touch USD 19.48 billion in 2021, at an estimated compound annual growth rate (CAGR) of 12.08 % during the forecast period. Major factors for the growth of the market are increasing use of SPECT and PET analysis in radiopharmaceuticals, increased awareness of people for radiopharmaceuticals, and ready availability of radiopharmaceuticals.
Novel applications such as Alzheimers and continually expanding oncology application segment also drive the market. Till now, SPECT imaging was the mainstream modality for nuclear medicine applications like nuclear cardiology procedures. However, the trend is soon going to flip upside down because of global shortage of molybdenum-99 isotope which is in turn will lead to shortage of Technetium-99, which is the daughter product of molybdenum. Hence, PET imaging products which includes hybrid PET-CT scanners holds a potential market size in coming years. The cost associated with PET-CT service contract is usually 105 of the system purchase price annually and can be as high as $275,000 per year. The emerging market trend is fusion of nuclear imaging with different diagnostic imaging products such as PET/CT, SPECT/CT, and MRI/PET. This provides full gamut of imaging scans through the same unit and at the same time. PET market is expected to witness more growth compared to SPECT imaging as it provides higher resolution images and the lack of availability of technetium-99m is propelling industry to look for alternative diagnostic procedures.
Get sample Copy of this report@ https://www.researchtrades.com/request-sample/1090962
Analyzing the application segment of SPECT and PET, PET is majorly being used in oncology because of good quality of imaging. While, SPECT is majorly used in cardiology segment accounting for almost 90% of the market share in cardiology. North America has 5729 PET procedures while the number of PET procedures in Asia-Pacific region is 369636 owing to the increased demand of nuclear medicine diagnostic procedures in developing nations. Market is segmented into two major segments SPECT (Technetium-99m (TC-99m), Thallium-201 (TL-201), Iodine (I-123) and others) and PET (Fluorine-18, Rubidium-82 (RB-82) and others). By application market is segmented into SPECT (cardiology, lymphoma, thyroid, neurology and others) and PET(oncology, cardiology, neurology and others).By geography market is segmented into North America, Europe and Asia-Pacific etc. North America accounts for the highest share of the global nuclear medicine diagnostic market; followed by Europe and Asia-Pacific. Asian countries are expected to show a growing trend in diagnostic sector because of increasing diagnostic procedure demand and rise in medical device industry.Major players in the market are Cardiarc Ltd., Digirad Corporation, Gamme Medica Inc., GE healthcare, Hologic Inc. etc. Mergers and acquisitions of small and medium sized manufacturers to enter in overseas market is another strategy adopted by multinational players.,
Purchase a copy of Global Nuclear Imaging Market, for the single user price of USD 4255 @ https://www.researchtrades.com/checkout/1090962
Table of Content
1. INTRODUCTION
1.1 MARKET DEFINITION
1.2 RESEARCH METHODOLOGY
2. EXECUTIVE SUMMARY
3. KEY INFERENCES
4. MARKET OVERVIEW AND INDUSTRY TRENDS
4.1 CURRENT MARKET SCENARIO
4.2. PORTERS FIVE FORCES ANALYSIS
4.2.1 BARGAINING POWER OF SUPPLIERS
4.2.2 BARGAINING POWER OF BUYERS
4.2.3 DEGREE OF COMPETITION
4.2.4 THREAT OF SUBSTITUTION
4.2.5 THREAT OF NEW ENTRANTS
5. DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES ANALYSIS (DROC)
5.1 MARKET DRIVERS
5.1.1 INCREASING NUMBER OF CANCER AND CARDIAC AILMENTS
5.1.2 INCREASING SPECT AND PET APPLICATIONS
5.1.3 GROWING PUBLIC AWARENESS FOR HEALTHCARE
5.2 MARKET RESTRAINTS
5.2.1 SHORT HALF-LIFE OF RADIOPHARMACEUTICALS
5.2.2 HIGH CAPITAL INVESTMENT
5.2.3 REGULATORY GUIDELINES
5.2.4 REIMBURSEMENT
5.3 KEY CHALLENGES
5.3.1 SHUTDOWN OF NUCLEAR REACTORS
5.4 CURRENT OPPORTUNITIES IN THE MARKET
5.4.1 INCREASING IMAGING TECHNOLOGIES
5.4.2 POTENTIAL RADIOISOTOPES IN PIPELINE
5.4.3 INCREASING NEUROLOGICAL APPLICATIONS
5.4.4 CYCLOTRON BASED PRODUCTION
If you have any special requirements, please let us know @ https://www.researchtrades.com/report-customization
6. GLOBAL NUCLEAR IMAGING MARKET SEGMENTATION
6.1 BY TYPE
6.1.1 SPECT RADIOISOTOPES
6.1.1.1 TECHNETIUM-99M (TC-99M)
6.1.1.2 THALLIUM-201 (TL-201)
6.1.1.3 IODINE-123 (I-123)
6.1.1.4 GALLIUM-67 (GA-67)
6.1.1.5 OTHERS
6.1.2 PET RADIOISOTOPES
6.1.2.1 FLUORINE-18
6.1.2.2 RUBIDIUM-82 (RB-82)
6.1.2.3 OTHERS
6.2 BY APPLICATIONS
6.2.1 SPECT
About us:
Research Trades has team of experts who works on providing exhaustive analysis pertaining to market research on a global basis. This comprehensive analysis is obtained by a thorough research and study of the ongoing trends and provides predictive data regarding the future estimations, which can be utilized by various organizations for growth purposes.
We distribute customized reports that focus on meeting the client’s specific requirement. Our database consists of a large collection of high-quality reports obtained using a customer-centric approach, thus providing valuable research insights.
Contact Info:
Name: Pranav Shelar
Email: sales@researchtrades.com
Organization: Research Trades
Phone: +1 6269994607
For more information, please visit https://www.researchtrades.com/report/global-nuclear-imaging-market-by-type-application-and-region-industry-analysis-size-share-growth-trends-and-forecasts-2016-2021/1090962
Source: MarketersMedia
Release ID: 217133
Copyright © 1999-2013 SproutNews.com
